Insider Transactions in Q1 2020 at Merck & Co., Inc. (MRK)
Insider Transaction List (Q1 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 28
2020
|
Robert M Davis Chairman, CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
33,396
+16.33%
|
$2,538,096
$76.56 P/Share
|
|
Feb 28
2020
|
Sanat Chattopadhyay Exe V-P & Pres. MMD |
BUY
Grant, award, or other acquisition
|
Direct |
15,785
+16.9%
|
$1,199,660
$76.56 P/Share
|
|
Feb 28
2020
|
Frank Clyburn EVP & Pres ? Human Health |
BUY
Grant, award, or other acquisition
|
Direct |
4,905
+5.97%
|
$372,780
$76.56 P/Share
|
|
Feb 28
2020
|
Richard R. De Luca EVP&Pres, Merck Animal Heallth |
BUY
Grant, award, or other acquisition
|
Direct |
14,374
+14.2%
|
$1,092,424
$76.56 P/Share
|
|
Feb 28
2020
|
Michael Fleming SVP Chief Ethics & Com Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,659
+26.88%
|
$126,084
$76.56 P/Share
|
|
Feb 28
2020
|
Kenneth C Frazier Executive Chair |
BUY
Grant, award, or other acquisition
|
Direct |
119,291
+13.21%
|
$9,066,116
$76.56 P/Share
|
|
Feb 28
2020
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,371
+14.24%
|
$560,196
$76.56 P/Share
|
|
Feb 28
2020
|
Rita A Karachun Sr. VP Fince-Global Controller |
BUY
Grant, award, or other acquisition
|
Direct |
4,269
+14.56%
|
$324,444
$76.56 P/Share
|
|
Feb 28
2020
|
Michael Nally EVP, Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,328
+27.2%
|
$252,928
$76.56 P/Share
|
|
Feb 28
2020
|
Roger M Perlmutter Exe V-P & Pres, MRL |
BUY
Grant, award, or other acquisition
|
Direct |
35,049
+14.05%
|
$2,663,724
$76.56 P/Share
|
|
Jan 13
2020
|
Julie L. Gerberding EVP, Chief Patient Officer |
SELL
Open market or private sale
|
Direct |
102,073
-73.38%
|
$9,084,497
$89.34 P/Share
|
|
Jan 13
2020
|
Julie L. Gerberding EVP, Chief Patient Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
82,548
+25.5%
|
-
|